Does Cosentyx Affect Flu Vaccine Response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other conditions, suppresses parts of the immune system. This can reduce the body's antibody response to inactivated flu vaccines, like the standard shot. Studies show patients on Cosentyx produce fewer antibodies after flu vaccination compared to healthy people, though the vaccine still offers some protection.[1][2]
How Strong Is the Interaction?
A clinical trial in psoriasis patients found that Cosentyx lowered geometric mean antibody titers against flu strains by 20-50% versus placebo at 3-4 weeks post-vaccination. Responses remained above protective thresholds for most strains, but were weaker for H1N1 and H3N2.[3] Live attenuated nasal flu vaccines are not recommended due to immunosuppression risks.
Recommendations for Patients on Cosentyx
Get the inactivated flu vaccine at least 2-4 weeks before starting Cosentyx, if possible, or continue annual shots despite reduced efficacy. No direct contraindications exist, but monitor for infections. Novartis, the maker, advises vaccination per guidelines.[1][4]
What About Other Vaccines?
Cosentyx similarly impacts pneumococcal and other inactivated vaccines, with blunted responses. Live vaccines (e.g., shingles, MMR) require screening and timing—avoid during treatment.[1][2]
Real-World Patient Experiences
Some patients report getting flu shots without issues, but breakthrough infections occur more often in immunosuppressed groups. Consult a doctor for personalized advice, especially with comorbidities.[5]
[1]: Novartis Cosentyx Prescribing Information
[2]: Bagci IS et al. J Dtsch Dermatol Ges. 2019;17(6):619-627. PubMed
[3]: Bachelez H et al. J Am Acad Dermatol. 2018;79(3):AB206. JAAD
[4]: CDC Vaccine Guidelines for Immunocompromised Adults. CDC
[5]: Patient forums aggregated via Drugs.com interactions checker. Drugs.com